NCT04063254Unknown2 期
A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases
适应症
干预措施
试验速览
- 阶段
- 2 期
- 入组人数
- 302
- 主要终点
- Effects of treatment
研究概览
简要总结
In the present study, we will prospectively evaluate the pain response and treatment failure rate to determine the most favorable radiation dose in single fraction stereotactic radiotherapy using the modern highly conformal technique for bone metastases. Our findings should be able to provide evidence-based recommendation to support the utilization of single fraction radiotherapy for value-based oncology practice.
详细描述
Primary objective To evaluate dose regimen for pain control in terms of rate of treatment failure, defined as the first occurrence of any of the following events, at 3 months
- Worsening in the worst pain score by at least 3 by brief pain inventory survey
- ≥ 50% increase in dose of opioid/narcotic medication
- Development of pathologic fracture or cord/nerve compression indicative of surgical intervention
- Unequivocal radiographic disease progression
Secondary objectives
- Compare pain response/control at the treated site(s) between the two treatment regimens by brief pain inventory survey
- Assess health-related quality of life for palliative cancer care patients (EORTC QLQ-C15-PAL & EORTC-BM22 Mandarin Taiwan)
- Evaluate the analgescis use after irradiation
- Evaluate acute and late adverse events associated with irradiation according to CTCAE criteria
- To evaluate the local control of the treated index site(s)
- To evaluate the patterns of failure
- To evlaute overall survival
- To evaluate the rate of re-irradiation, salvage surgery, interventional procedure, and MR-guided high intensity focused ultrasound at the treated site(s)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with a histologic diagnosis of non-hematopoietic malignancy
- •Radiographic evidence of bone metastases
- •Patient with pain or dysathesia on a pain score of at least 2 by brief pain inventory survey
- •Multiple osseous sites are eligible with a maximum of three separate sites irradiated concurrently
- •Patients do not have prior radiotherapy or radiosurgery to the index site(s)
- •Age ≥ 20 years
- •Karnofsky performance status (KPS) ≥ 50%.
- •Life expectancy of ≥ 3 months
- •Women of childbearing potential and male participants must practice adequate contraception
- •Patients must be able to comply with the study protocol, pain assessment, quality of life survey, and follow-up schedules and provide study-specific informed consent
排除标准
- •Patients with radiographic impending or pathological fracture, or malignant epidural cord compression at the index site(s) indicative of upfront surgery
- •Prior radiotherapy or radiosurgery to the index site(s)
- •Previously treated with radioactive isotope (e.g. Ra-223) within 30 days of registration
- •Inability to cooperate treatment procedure
- •Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:
- •Uncontrolled active infection requiring intravenous antibiotics at the time of registration
- •Transmural myocardial infarction ≤ 6 months prior to registration
- •Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration
- •Life-threatening uncontrolled clinically significant cardiac arrhythmias
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- •Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- •Uncontrolled psychiatric disorder
- •Will receive any other investigational agent or chemotherapy during treatment
- •Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic
- •Pregnant or breast-feeding women
研究组 & 干预措施
High-Dose Stereotactic Radiotherapy
Experimental
干预措施: Stereotactic Radiotherapy (Radiation)
Standard-Dose Stereotactic Radiotherapy
Active Comparator
干预措施: Stereotactic Radiotherapy (Radiation)
结局指标
主要结局
Effects of treatment
时间窗: 3 months
To evaluate dose regimen for pain control in terms of rate of treatment failure, defined as the first occurrence of any of the following events
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
The STEPS - Totalis™ TrialLumbar Spinal StenosisNCT02079038VertiFlex, Incorporated180
终止
不适用
High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast CarcinomaBreast CancerNCT00165581Dana-Farber Cancer Institute15
撤回
不适用
Pain as Indication for Operative Treatment of Traumatic Rib FracturesTraumaRib FracturesSurgeryPainNCT02094807Sahlgrenska University Hospital, Sweden
招募中
3 期
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AMLRefractory Acute Myeloid LeukemiaEarly Relapses of Acute Myeloid LeukemiaNCT06418776National Research Center for Hematology, Russia198
已完成
不适用
Prospective Randomized Feasibility Study Comparing Manual vs. Automatic Position-Adaptive Spinal Cord Stimulation With Surgical LeadsChronic Refractory Low Back and Leg PainNCT01874899Justin Parker Neurological Institute18